This 2023 randomized controlled trial investigated the impact of sleep duration and quality on weight loss maintenance in adults with obesity. After an initial 8-week low-calorie diet resulting in an average weight loss of 13.1 kg, participants were monitored over a 1-year maintenance phase. Those with short sleep duration (5)
This 1994 review analyzed 20 English-language studies from 1967 to March 1993, focusing on the impact of pharmacologic therapy lasting ≥6 months on weight loss and maintenance. Agents studied included phentermine, mazindol, fenfluramine, dexfenfluramine, and fluoxetine. While initial weight loss varied across studies, a plateau or weight regain was commonly
This 2014 retrospective audit evaluated the safety, tolerability, and efficacy of combination phentermine and topiramate therapy for weight maintenance in 103 patients at the Austin Health Weight Control Clinic. Patients initially achieved a 10% weight loss through a very low energy diet (VLED). Among them, 61 discontinued the combination therapy,
This 2024 case report evaluates the effects of a twice-weekly 36-hour intermittent fasting (IF) regimen on metabolic parameters and weight maintenance over 82 weeks. The study compared a 5:2 non-consecutive fasting protocol (5:2-NC) with a modified 4:3 protocol (M4:3-NC) that included a 500–600 kcal meal on fasting days. Findings revealed
This 2006 review article examines the efficacy and considerations of Very Low Energy Diets (VLEDs) in obesity treatment. VLEDs provide between 450 and 800 kcal/day, delivering complete nutritional requirements. They induce rapid weight loss, typically 1.5–2.5 kg/week, through mechanisms like mild ketosis, which suppresses hunger and preserves lean body mass.
This randomized controlled trial evaluated the efficacy of a very low-calorie diet (VLCD), behavior therapy (BT), and their combination in treating obesity. Seventy-six obese women were assigned to one of the three interventions. At the end of treatment, weight losses were 13.1 kg (VLCD), 13.0 kg (BT), and 16.8 kg
This randomized controlled trial evaluated 49 obese women over a 52-week behavioral program, comparing a balanced deficit diet (BDD; 1,200 kcal/day) with a very-low-calorie diet (VLCD; 420 kcal/day for 16 weeks, then 1,200 kcal/day). At 26 weeks, the VLCD group achieved greater weight loss (mean 21.45 kg) than the BDD
This study assessed the efficacy and safety of IQP-PV-101, a proprietary extract of Phaseolus vulgaris, in weight management. In the 12-week double-blind, placebo-controlled weight loss phase, participants adhering to a mildly hypocaloric diet received either IQP-PV-101 or placebo. The IQP-PV-101 group experienced a significant mean weight loss of 2.91 ±
This 2-year, multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of orlistat (120 mg three times daily) in 743 obese patients (BMI 28–47 kg/m²) across 15 European centers. Following a 4-week lead-in period with a hypocaloric diet, 688 participants were randomized to receive orlistat or placebo alongside dietary
This 1997 randomized controlled trial evaluated whether daily supplementation of 20 g of water-soluble fiber (guar gum) over 14 months could aid in weight maintenance among 31 obese women following a very-low-calorie diet (VLCD). Participants were divided into a fiber group and a control group. The fiber group was further
